Tag: Oncology
Invivoscribe, Complete Genomics to develop biomarker tests for oncology research
Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s next-generation sequencing (NGS) platforms. The collaboration, covering ... Read More
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More
Hanx Biopharmaceuticals set to begin US clinical trial of HX009 in lymphoma
Hanx Biopharmaceuticals (HanxBio) has obtained approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) of HX009, enabling the company ... Read More
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration (FDA) for the treatment of relapsed or ... Read More
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug conjugate (ADC) called LM-305 with AstraZeneca. LM-305 ... Read More
Quest Diagnostics to add ctDNA detection technology with Haystack Oncology
Quest Diagnostics, an American diagnostic information services provider, has agreed to acquire early-stage oncology company Haystack Oncology in an all-cash deal worth up to $450 ... Read More
ImmunoGen to get nearly $175m financing from Pharmakon Advisors
ImmunoGen, a US-based biotechnology company, will receive a non-dilutive term loan financing facility for up to $175 million from entities managed by Pharmakon Advisors. The ... Read More
Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
Sesen Bio gets shareholders’ approval for merger with Carisma Therapeutics
Nasdaq-listed Sesen Bio said that its stockholders have approved the previously announced merger deal with Carisma Therapeutics aimed at creating a clinical-stage biotechnology company for ... Read More
